Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Arcus Biosciences, Inc.RCUS · Entity 4104 | Director | June 11, 2026 | June 12, 2026 |
| COLLEGIUM PHARMACEUTICAL, INCCOLL · Entity 5169 | 10% owner | December 05, 2017 | December 08, 2017 |
| SI-BONE, Inc.SIBN · Entity 2501 | 10% owner | October 19, 2018 | October 19, 2018 |
| SUTRO BIOPHARMA, INC.STRO · Entity 5797 | 10% owner | October 01, 2018 | October 03, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Arcus Biosciences, Inc.
Report date June 11, 2026 · Filed June 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 25,700 |
Reported balance
After 2026-06-11 transaction · row 1
1 source rowRow 1 · 2026-06-11 · Grant · Acquired 5,700 · Balance 25,700 F1: Represents the grant of restricted stock units that vest in full on the earlier of June 11, 2027 or the next annual meeting of stockholders of the issuer. The RSUs will become fully vested in the event the Company is subject to a change in control. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.30 · Expires 2036-06-10 | Direct | 16,900 |
Reported balance
After 2026-06-11 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-06-11 · Grant · Acquired 16,900 · Balance 16,900 F3: The option will vest in full on the earlier of June 11, 2027 or the next annual meeting of stockholders of the issuer. The option will become fully vested and exercisable in the event the Company is subject to a change in control. |
| Common StockSEC Table I · non-derivative | IndirectBy Kaneko Investments, LLC | 252,524 |
Reported balance
Holding disclosure · report date 2026-06-11 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 252,524 |
| Common StockSEC Table I · non-derivative | IndirectBy Kaneko Capital, LLC | 505,050 |
Reported balance
Holding disclosure · report date 2026-06-11 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 505,050 |
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 174,681 |
Reported balance
Holding disclosure · report date 2026-06-11 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 174,681 F2: Includes 13,300 shares of restricted stock units (previously reported) that vested on June 11, 2026 and were subsequently transferred to the reporting person's trust. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the grant of restricted stock units that vest in full on the earlier of June 11, 2027 or the next annual meeting of stockholders of the issuer. The RSUs will become fully vested in the event the Company is subject to a change in control.
F2: Includes 13,300 shares of restricted stock units (previously reported) that vested on June 11, 2026 and were subsequently transferred to the reporting person's trust.
F3: The option will vest in full on the earlier of June 11, 2027 or the next annual meeting of stockholders of the issuer. The option will become fully vested and exercisable in the event the Company is subject to a change in control.
COLLEGIUM PHARMACEUTICAL, INC
Report date December 05, 2017 · Filed December 08, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Skyline Venture Partners V, L.P. | 2,149,916 |
Reported balance
After 2017-12-05 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2017-12-05 · Other · Disposed 800,000 · Balance 2,149,916 F1: Represents a pro rata in-kind distribution of the shares by Skyline Venture Partners V, L.P. without consideration to its limited and general partners. F2: The shares are held by Skyline Venture Partners V, L.P. The general partner of Skyline Venture Partners V, L.P. is Skyline Venture Management V, LLC. John G. Freund and Yasunori Kaneko are managers of Skyline Venture Management V, LLC. These individuals share voting and investment power over the shares held by Skyline Venture Management, LLC. Dr. Kaneko disclaims beneficial ownership of all the shares held by Skyline Venture Partners V, L.P. except to the extent of his proportionate pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy the Kaneko Family Trust | 270 |
Reported balance
After 2017-12-05 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2017-12-05 · Other · Acquired 270 · Balance 270 F3: Represents a pro rata in-kind distribution of the shares by Skyline Venture Partners V, L.P. without consideration to the reporting person. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a pro rata in-kind distribution of the shares by Skyline Venture Partners V, L.P. without consideration to its limited and general partners.
F2: The shares are held by Skyline Venture Partners V, L.P. The general partner of Skyline Venture Partners V, L.P. is Skyline Venture Management V, LLC. John G. Freund and Yasunori Kaneko are managers of Skyline Venture Management V, LLC. These individuals share voting and investment power over the shares held by Skyline Venture Management, LLC. Dr. Kaneko disclaims beneficial ownership of all the shares held by Skyline Venture Partners V, L.P. except to the extent of his proportionate pecuniary interest therein.
F3: Represents a pro rata in-kind distribution of the shares by Skyline Venture Partners V, L.P. without consideration to the reporting person.
SI-BONE, Inc.
Report date October 19, 2018 · Filed October 19, 2018
Jointly reported with Skyline Venture Partners V LP, Skyline Venture Management V, LLC, Freund John Gordon
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Skyline Venture Partners V, L.P. | 4,419,985 |
Last balance in matching sequence
After 2018-10-19 transaction · row 5
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
5 source rowsRow 1 · 2018-10-19 · Conversion · Acquired 2,213,425 · Balance 2,213,425 F1: The Issuer's Series 4 Preferred Stock, Series 5 Preferred Stock and Series 7 Preferred Stock automatically converted into an equal number of shares of Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date. F2: Shares held by Skyline Venture Partners V, L.P. ("SVP V"). Skyline Venture Management V, LLC ("LLC") is the general partner of SVP V and as such may be deemed to have voting and investment power with respect to the securities of SVP V. John G. Freund, a member of the Issuer's board of directors, together with Yasunori Kaneko, are the managing directors of LLC and each may be deemed to have voting and investment power with respect to the securities held by SVP V. Dr. Freund and Mr. Kaneko disclaim beneficial ownership of such securities, except to the extent of their pecuniary interest therein. Row 2 · 2018-10-19 · Conversion · Acquired 792,195 · Balance 3,005,620 F1: The Issuer's Series 4 Preferred Stock, Series 5 Preferred Stock and Series 7 Preferred Stock automatically converted into an equal number of shares of Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date. F2: Shares held by Skyline Venture Partners V, L.P. ("SVP V"). Skyline Venture Management V, LLC ("LLC") is the general partner of SVP V and as such may be deemed to have voting and investment power with respect to the securities of SVP V. John G. Freund, a member of the Issuer's board of directors, together with Yasunori Kaneko, are the managing directors of LLC and each may be deemed to have voting and investment power with respect to the securities held by SVP V. Dr. Freund and Mr. Kaneko disclaim beneficial ownership of such securities, except to the extent of their pecuniary interest therein. Row 3 · 2018-10-19 · Conversion · Acquired 690,689 · Balance 3,696,309 F3: The Issuer's Series 6 Preferred Stock automatically converted into approximately 1.05878 shares of Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date. F2: Shares held by Skyline Venture Partners V, L.P. ("SVP V"). Skyline Venture Management V, LLC ("LLC") is the general partner of SVP V and as such may be deemed to have voting and investment power with respect to the securities of SVP V. John G. Freund, a member of the Issuer's board of directors, together with Yasunori Kaneko, are the managing directors of LLC and each may be deemed to have voting and investment power with respect to the securities held by SVP V. Dr. Freund and Mr. Kaneko disclaim beneficial ownership of such securities, except to the extent of their pecuniary interest therein. Row 4 · 2018-10-19 · Conversion · Acquired 398,676 · Balance 4,094,985 F1: The Issuer's Series 4 Preferred Stock, Series 5 Preferred Stock and Series 7 Preferred Stock automatically converted into an equal number of shares of Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date. F2: Shares held by Skyline Venture Partners V, L.P. ("SVP V"). Skyline Venture Management V, LLC ("LLC") is the general partner of SVP V and as such may be deemed to have voting and investment power with respect to the securities of SVP V. John G. Freund, a member of the Issuer's board of directors, together with Yasunori Kaneko, are the managing directors of LLC and each may be deemed to have voting and investment power with respect to the securities held by SVP V. Dr. Freund and Mr. Kaneko disclaim beneficial ownership of such securities, except to the extent of their pecuniary interest therein. Row 5 · 2018-10-19 · Purchase · Acquired 325,000 · Balance 4,419,985 F2: Shares held by Skyline Venture Partners V, L.P. ("SVP V"). Skyline Venture Management V, LLC ("LLC") is the general partner of SVP V and as such may be deemed to have voting and investment power with respect to the securities of SVP V. John G. Freund, a member of the Issuer's board of directors, together with Yasunori Kaneko, are the managing directors of LLC and each may be deemed to have voting and investment power with respect to the securities held by SVP V. Dr. Freund and Mr. Kaneko disclaim beneficial ownership of such securities, except to the extent of their pecuniary interest therein. |
| Warrant (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.10 | IndirectBy Skyline Venture Partners V, L.P. | 0 |
Reported balance
After 2018-10-19 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2018-10-19 · Other · Disposed 39,421 · Balance 0 F4: Shares subject to the warrant are immediately exercisable. The warrant will expire in connection with the closing of the Issuer's initial public offering. F2: Shares held by Skyline Venture Partners V, L.P. ("SVP V"). Skyline Venture Management V, LLC ("LLC") is the general partner of SVP V and as such may be deemed to have voting and investment power with respect to the securities of SVP V. John G. Freund, a member of the Issuer's board of directors, together with Yasunori Kaneko, are the managing directors of LLC and each may be deemed to have voting and investment power with respect to the securities held by SVP V. Dr. Freund and Mr. Kaneko disclaim beneficial ownership of such securities, except to the extent of their pecuniary interest therein. |
| Series 5 Preferred StockSEC Table II · derivative / convertible security · Conversion / exercise price $9.10 | IndirectBy Skyline Venture Partners V, L.P. | 816,099 |
Reported balance
After 2018-10-19 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2018-10-19 · Other · Acquired 39,421 · Balance 816,099 F1: The Issuer's Series 4 Preferred Stock, Series 5 Preferred Stock and Series 7 Preferred Stock automatically converted into an equal number of shares of Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date. F2: Shares held by Skyline Venture Partners V, L.P. ("SVP V"). Skyline Venture Management V, LLC ("LLC") is the general partner of SVP V and as such may be deemed to have voting and investment power with respect to the securities of SVP V. John G. Freund, a member of the Issuer's board of directors, together with Yasunori Kaneko, are the managing directors of LLC and each may be deemed to have voting and investment power with respect to the securities held by SVP V. Dr. Freund and Mr. Kaneko disclaim beneficial ownership of such securities, except to the extent of their pecuniary interest therein. |
| Series 5 Preferred StockSEC Table II · derivative / convertible security | IndirectBy Skyline Venture Partners V, L.P. | 792,195 |
Reported balance
After 2018-10-19 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2018-10-19 · Sale · Disposed 23,904 · Balance 792,195 F1: The Issuer's Series 4 Preferred Stock, Series 5 Preferred Stock and Series 7 Preferred Stock automatically converted into an equal number of shares of Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date. F5: Immediately prior to the closing of the Issuer's initial public offering, SVP V exercised a warrant to purchase 39,421 shares of Series 5 Preferred Stock at an exercise price of $9.10 per share. The exercise price was paid on a net exercise cashless basis calculated using the Issuer's initial public offering price of $15.00, resulting in the Issuer withholding 23,904 of the warrant shares to pay the exercise price and issuing SVP V the remaining 15,517 shares. F2: Shares held by Skyline Venture Partners V, L.P. ("SVP V"). Skyline Venture Management V, LLC ("LLC") is the general partner of SVP V and as such may be deemed to have voting and investment power with respect to the securities of SVP V. John G. Freund, a member of the Issuer's board of directors, together with Yasunori Kaneko, are the managing directors of LLC and each may be deemed to have voting and investment power with respect to the securities held by SVP V. Dr. Freund and Mr. Kaneko disclaim beneficial ownership of such securities, except to the extent of their pecuniary interest therein. |
| Series 5 Preferred StockSEC Table II · derivative / convertible security | IndirectBy Skyline Venture Partners V, L.P. | 0 |
Reported balance
After 2018-10-19 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2018-10-19 · Conversion · Disposed 792,195 · Balance 0 F1: The Issuer's Series 4 Preferred Stock, Series 5 Preferred Stock and Series 7 Preferred Stock automatically converted into an equal number of shares of Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date. F2: Shares held by Skyline Venture Partners V, L.P. ("SVP V"). Skyline Venture Management V, LLC ("LLC") is the general partner of SVP V and as such may be deemed to have voting and investment power with respect to the securities of SVP V. John G. Freund, a member of the Issuer's board of directors, together with Yasunori Kaneko, are the managing directors of LLC and each may be deemed to have voting and investment power with respect to the securities held by SVP V. Dr. Freund and Mr. Kaneko disclaim beneficial ownership of such securities, except to the extent of their pecuniary interest therein. |
| Series 4 Preferred StockSEC Table II · derivative / convertible security | IndirectBy Skyline Venture Partners V, L.P. | 0 |
Reported balance
After 2018-10-19 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2018-10-19 · Conversion · Disposed 2,213,425 · Balance 0 F1: The Issuer's Series 4 Preferred Stock, Series 5 Preferred Stock and Series 7 Preferred Stock automatically converted into an equal number of shares of Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date. F2: Shares held by Skyline Venture Partners V, L.P. ("SVP V"). Skyline Venture Management V, LLC ("LLC") is the general partner of SVP V and as such may be deemed to have voting and investment power with respect to the securities of SVP V. John G. Freund, a member of the Issuer's board of directors, together with Yasunori Kaneko, are the managing directors of LLC and each may be deemed to have voting and investment power with respect to the securities held by SVP V. Dr. Freund and Mr. Kaneko disclaim beneficial ownership of such securities, except to the extent of their pecuniary interest therein. |
| Series 6 Preferred StockSEC Table II · derivative / convertible security | IndirectBy Skyline Venture Partners V, L.P. | 0 |
Reported balance
After 2018-10-19 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2018-10-19 · Conversion · Disposed 652,347 · Balance 0 F3: The Issuer's Series 6 Preferred Stock automatically converted into approximately 1.05878 shares of Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date. F2: Shares held by Skyline Venture Partners V, L.P. ("SVP V"). Skyline Venture Management V, LLC ("LLC") is the general partner of SVP V and as such may be deemed to have voting and investment power with respect to the securities of SVP V. John G. Freund, a member of the Issuer's board of directors, together with Yasunori Kaneko, are the managing directors of LLC and each may be deemed to have voting and investment power with respect to the securities held by SVP V. Dr. Freund and Mr. Kaneko disclaim beneficial ownership of such securities, except to the extent of their pecuniary interest therein. |
| Series 7 Preferred StockSEC Table II · derivative / convertible security | IndirectBy Skyline Venture Partners V, L.P. | 0 |
Reported balance
After 2018-10-19 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2018-10-19 · Conversion · Disposed 398,676 · Balance 0 F1: The Issuer's Series 4 Preferred Stock, Series 5 Preferred Stock and Series 7 Preferred Stock automatically converted into an equal number of shares of Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date. F2: Shares held by Skyline Venture Partners V, L.P. ("SVP V"). Skyline Venture Management V, LLC ("LLC") is the general partner of SVP V and as such may be deemed to have voting and investment power with respect to the securities of SVP V. John G. Freund, a member of the Issuer's board of directors, together with Yasunori Kaneko, are the managing directors of LLC and each may be deemed to have voting and investment power with respect to the securities held by SVP V. Dr. Freund and Mr. Kaneko disclaim beneficial ownership of such securities, except to the extent of their pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The Issuer's Series 4 Preferred Stock, Series 5 Preferred Stock and Series 7 Preferred Stock automatically converted into an equal number of shares of Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date.
F2: Shares held by Skyline Venture Partners V, L.P. ("SVP V"). Skyline Venture Management V, LLC ("LLC") is the general partner of SVP V and as such may be deemed to have voting and investment power with respect to the securities of SVP V. John G. Freund, a member of the Issuer's board of directors, together with Yasunori Kaneko, are the managing directors of LLC and each may be deemed to have voting and investment power with respect to the securities held by SVP V. Dr. Freund and Mr. Kaneko disclaim beneficial ownership of such securities, except to the extent of their pecuniary interest therein.
F3: The Issuer's Series 6 Preferred Stock automatically converted into approximately 1.05878 shares of Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date.
F4: Shares subject to the warrant are immediately exercisable. The warrant will expire in connection with the closing of the Issuer's initial public offering.
F5: Immediately prior to the closing of the Issuer's initial public offering, SVP V exercised a warrant to purchase 39,421 shares of Series 5 Preferred Stock at an exercise price of $9.10 per share. The exercise price was paid on a net exercise cashless basis calculated using the Issuer's initial public offering price of $15.00, resulting in the Issuer withholding 23,904 of the warrant shares to pay the exercise price and issuing SVP V the remaining 15,517 shares.
SUTRO BIOPHARMA, INC.
Report date October 01, 2018 · Filed October 03, 2018
Jointly reported with Skyline Venture Partners V LP, Skyline Venture Management V, LLC
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Skyline Venture Partners V, L.P. | 1,960,053 |
Last balance in matching sequence
After 2018-10-01 transaction · row 3
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
3 source rowsRow 1 · 2018-10-01 · Conversion · Acquired 925,578 · Balance 925,578 F1: Each share of the issuer's Series C Preferred Stock automatically converted into 0.0370 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its firm commitment initial public offering (the "IPO") pursuant to a registration statement on Form S-1 (File No. 333-227103) under the Securities Act of 1933, as amended (the "Registration Statement"), and had no expiration date. F2: These securities are held of record by Skyline Venture Partners V, L.P. ("Skyline L.P."). Skyline Venture Management V, LLC ("Skyline Management") is the general partner of Skyline L.P. John G. Freund and Yasunori Kaneko, are the managing directors of Skyline Management, and each may be deemed to share voting and investment power over the securities held by Skyline L.P. and disclaims beneficial ownership over such securities except to the extent of their pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. Mr. Freund is a director of the Issuer and, accordingly, files separate Section 16 reports. Row 2 · 2018-10-01 · Conversion · Acquired 520,264 · Balance 1,445,842 F3: Each share of the issuer's Series D Preferred Stock automatically converted into 0.0405 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F2: These securities are held of record by Skyline Venture Partners V, L.P. ("Skyline L.P."). Skyline Venture Management V, LLC ("Skyline Management") is the general partner of Skyline L.P. John G. Freund and Yasunori Kaneko, are the managing directors of Skyline Management, and each may be deemed to share voting and investment power over the securities held by Skyline L.P. and disclaims beneficial ownership over such securities except to the extent of their pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. Mr. Freund is a director of the Issuer and, accordingly, files separate Section 16 reports. Row 3 · 2018-10-01 · Conversion · Acquired 514,211 · Balance 1,960,053 F4: Each share of the issuer's Series E Preferred Stock automatically converted into 0.0275 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F2: These securities are held of record by Skyline Venture Partners V, L.P. ("Skyline L.P."). Skyline Venture Management V, LLC ("Skyline Management") is the general partner of Skyline L.P. John G. Freund and Yasunori Kaneko, are the managing directors of Skyline Management, and each may be deemed to share voting and investment power over the securities held by Skyline L.P. and disclaims beneficial ownership over such securities except to the extent of their pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. Mr. Freund is a director of the Issuer and, accordingly, files separate Section 16 reports. |
| Series C Preferred StockSEC Table II · derivative / convertible security | IndirectBy Skyline Venture Partners V, L.P. | 0 |
Reported balance
After 2018-10-01 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2018-10-01 · Conversion · Disposed 25,015,635 · Balance 0 F1: Each share of the issuer's Series C Preferred Stock automatically converted into 0.0370 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its firm commitment initial public offering (the "IPO") pursuant to a registration statement on Form S-1 (File No. 333-227103) under the Securities Act of 1933, as amended (the "Registration Statement"), and had no expiration date. F2: These securities are held of record by Skyline Venture Partners V, L.P. ("Skyline L.P."). Skyline Venture Management V, LLC ("Skyline Management") is the general partner of Skyline L.P. John G. Freund and Yasunori Kaneko, are the managing directors of Skyline Management, and each may be deemed to share voting and investment power over the securities held by Skyline L.P. and disclaims beneficial ownership over such securities except to the extent of their pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. Mr. Freund is a director of the Issuer and, accordingly, files separate Section 16 reports. |
| Series D Preferred StockSEC Table II · derivative / convertible security | IndirectBy Skyline Venture Partners V, L.P. | 0 |
Reported balance
After 2018-10-01 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2018-10-01 · Conversion · Disposed 12,846,023 · Balance 0 F3: Each share of the issuer's Series D Preferred Stock automatically converted into 0.0405 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F2: These securities are held of record by Skyline Venture Partners V, L.P. ("Skyline L.P."). Skyline Venture Management V, LLC ("Skyline Management") is the general partner of Skyline L.P. John G. Freund and Yasunori Kaneko, are the managing directors of Skyline Management, and each may be deemed to share voting and investment power over the securities held by Skyline L.P. and disclaims beneficial ownership over such securities except to the extent of their pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. Mr. Freund is a director of the Issuer and, accordingly, files separate Section 16 reports. |
| Series E Preferred StockSEC Table II · derivative / convertible security | IndirectBy Skyline Venture Partners V, L.P. | 0 |
Reported balance
After 2018-10-01 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2018-10-01 · Conversion · Disposed 18,698,578 · Balance 0 F4: Each share of the issuer's Series E Preferred Stock automatically converted into 0.0275 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F2: These securities are held of record by Skyline Venture Partners V, L.P. ("Skyline L.P."). Skyline Venture Management V, LLC ("Skyline Management") is the general partner of Skyline L.P. John G. Freund and Yasunori Kaneko, are the managing directors of Skyline Management, and each may be deemed to share voting and investment power over the securities held by Skyline L.P. and disclaims beneficial ownership over such securities except to the extent of their pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. Mr. Freund is a director of the Issuer and, accordingly, files separate Section 16 reports. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share of the issuer's Series C Preferred Stock automatically converted into 0.0370 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its firm commitment initial public offering (the "IPO") pursuant to a registration statement on Form S-1 (File No. 333-227103) under the Securities Act of 1933, as amended (the "Registration Statement"), and had no expiration date.
F2: These securities are held of record by Skyline Venture Partners V, L.P. ("Skyline L.P."). Skyline Venture Management V, LLC ("Skyline Management") is the general partner of Skyline L.P. John G. Freund and Yasunori Kaneko, are the managing directors of Skyline Management, and each may be deemed to share voting and investment power over the securities held by Skyline L.P. and disclaims beneficial ownership over such securities except to the extent of their pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. Mr. Freund is a director of the Issuer and, accordingly, files separate Section 16 reports.
F3: Each share of the issuer's Series D Preferred Stock automatically converted into 0.0405 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date.
F4: Each share of the issuer's Series E Preferred Stock automatically converted into 0.0275 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 11, 2026 Filed Jun 12, 2026 20:28 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | GrantStock Option (Right to Buy) · Derivative | 16,900 | $0.00 Strike: $23.30 | $0.00 |
DisclosureSEC source: 0001277503-26-000003 · wk-form4_1781296095.xml · derivative · entry 5 KANEKO YASUNORI · CIK 0001277503 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,900 Underlying: Stock Option (Rights to Buy) · 16,900 shares Expires 2036-06-10 F3 · derivative.exercise_date: The option will vest in full on the earlier of June 11, 2027 or the next annual meeting of stockholders of the issuer. The option will become fully vested and exercisable in the event the Company is subject to a change in control. Read SEC document |
| June 11, 2026 Filed Jun 12, 2026 20:28 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | GrantCommon Stock | 5,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001277503-26-000003 · wk-form4_1781296095.xml · nonDerivative · entry 1 KANEKO YASUNORI · CIK 0001277503 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,700 F1 · shares: Represents the grant of restricted stock units that vest in full on the earlier of June 11, 2027 or the next annual meeting of stockholders of the issuer. The RSUs will become fully vested in the event the Company is subject to a change in control. Read SEC document |
| June 10, 2025 Filed Jun 12, 2025 20:28 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | GrantStock Option (Right to Buy) · Derivative | 38,300 | $0.00 Strike: $10.02 | $0.00 |
DisclosureSEC source: 0001724521-25-000087 · wk-form4_1749760080.xml · derivative · entry 5 KANEKO YASUNORI · CIK 0001277503 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,300 Underlying: Common Stock · 38,300 shares Expires 2035-06-09 F2 · derivative.exercise_date: The option will vest in full on the earlier of June 10, 2026 or the next annual meeting of stockholders of the issuer. The option will become fully vested and exercisable in the event the Company is subject to a change in control. Read SEC document |
| June 10, 2025 Filed Jun 12, 2025 20:28 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | GrantCommon Stock | 13,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001724521-25-000087 · wk-form4_1749760080.xml · nonDerivative · entry 1 KANEKO YASUNORI · CIK 0001277503 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,300 F1 · shares: Represents the grant of restricted stock units that vest in full on the earlier of June 10, 2026 or the next annual meeting of stockholders of the issuer. The RSUs will become fully vested in the event the Company is subject to a change in control. Read SEC document |
| February 27, 2025 Filed Feb 28, 2025 00:06 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | PurchaseCommon Stock | 20,000 | $10.06 | $201,200.00 |
DisclosureSEC source: 0001724521-25-000046 · wk-form4_1740701159.xml · nonDerivative · entry 1 KANEKO YASUNORI · CIK 0001277503 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,400 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.00 to $10.16, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| June 06, 2024 Filed Jun 7, 2024 22:21 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | GrantStock Option (Right to Buy) · Derivative | 24,000 | $0.00 Strike: $15.90 | $0.00 |
DisclosureSEC source: 0001724521-24-000116 · wk-form4_1717798857.xml · derivative · entry 5 KANEKO YASUNORI · CIK 0001277503 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock · 24,000 shares Expires 2034-06-05 F2 · derivative.exercise_date: The option will vest in full on the earlier of June 6, 2025 or the next annual meeting of stockholders of the issuer. The option will become fully vested and exercisable in the event the Company is subject to a change in control. Read SEC document |
| June 06, 2024 Filed Jun 7, 2024 22:21 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | GrantCommon Stock | 8,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001724521-24-000116 · wk-form4_1717798857.xml · nonDerivative · entry 1 KANEKO YASUNORI · CIK 0001277503 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,200 F1 · shares: Represents the grant of restricted stock units that vest in full on the earlier of June 6, 2025 or the next annual meeting of stockholders of the issuer. The RSUs will become fully vested in the event the Company is subject to a change in control. Read SEC document |
| June 15, 2023 Filed Jun 17, 2023 00:03 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | GrantStock Option (Right to Buy) · Derivative | 19,500 | $0.00 Strike: $19.60 | $0.00 |
DisclosureSEC source: 0001209191-23-038141 · doc4.xml · derivative · entry 5 KANEKO YASUNORI · CIK 0001277503 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,500 Underlying: Common Stock · 19,500 shares Expires 2033-06-14 F3 · derivative.exercise_date: The option will vest in full on the earlier of June 15, 2024 or the next annual meeting of stockholders of the issuer. The option will become fully vested and exercisable in the event the Company is subject to a change in control. Read SEC document |
| June 15, 2023 Filed Jun 17, 2023 00:03 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | GrantCommon Stock | 6,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-038141 · doc4.xml · nonDerivative · entry 1 KANEKO YASUNORI · CIK 0001277503 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,800 F1 · shares: Represents the grant of restricted stock units that vest in full on the earlier of June 15, 2024 or the next annual meeting of stockholders of the issuer. The RSUs will become fully vested in the event the Company is subject to a change in control. Read SEC document |
| June 14, 2022 Filed Jun 16, 2022 20:21 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | GrantStock Option (Right to Buy) · Derivative | 16,800 | $0.00 Strike: $20.62 | $0.00 |
DisclosureSEC source: 0001209191-22-037409 · doc4.xml · derivative · entry 5 KANEKO YASUNORI · CIK 0001277503 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,800 Underlying: Common Stock · 16,800 shares Expires 2032-06-13 F3 · derivative.exercise_date: The option will vest in full on the earlier of June 14, 2023 or the next annual meeting of stockholders of the issuer. The option will become fully vested and exercisable in the event the Company is subject to a change in control. Read SEC document |
| June 14, 2022 Filed Jun 16, 2022 20:21 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | GrantCommon Stock | 4,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-037409 · doc4.xml · nonDerivative · entry 1 KANEKO YASUNORI · CIK 0001277503 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,100 F1 · shares: Represents the grant of restricted stock units that vest in full on the earlier of June 14, 2023 or the next annual meeting of stockholders of the issuer. The RSUs will become fully vested in the event the Company is subject to a change in control. Read SEC document |
| June 03, 2021 Filed Jun 7, 2021 20:36 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | GrantStock Option (Right to Buy) · Derivative | 14,100 | $0.00 Strike: $24.79 | $0.00 |
DisclosureSEC source: 0001209191-21-038619 · doc4.xml · derivative · entry 5 KANEKO YASUNORI · CIK 0001277503 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,100 Underlying: Common Stock · 14,100 shares Expires 2031-06-02 F4 · derivative.exercise_date: The option will vest in full on the earlier of (i) 12 months following the date of grant or (ii) the date of the next annual stockholder meeting following the grant. The option becomes fully vested and exercisable in the event the Company is subject to a change in control. Read SEC document |
| June 03, 2021 Filed Jun 7, 2021 20:36 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | GrantCommon Stock | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-038619 · doc4.xml · nonDerivative · entry 1 KANEKO YASUNORI · CIK 0001277503 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 F1 · shares: Represents the grant of restricted stock units that vest 100% on the earlier of June 3, 2022 or the next annual meeting of the stockholders of the issuer. The RSUs will become fully vested in the event the Company is subject to a change in control. F2 · balance_after: Includes 3,000 shares of restricted stock units (previously reported) that vested on June 3, 2021. F3 · balance_after: Four thousand one hundred thirty-three (4,133) shares previously held directly by the reporting person were transferred to reporting person's trust. Read SEC document |
| April 23, 2021 Filed Apr 26, 2021 20:16 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | PurchaseCommon Stock | 4,133 | $31.37 | $129,652.21 |
DisclosureSEC source: 0001179110-21-004605 · edgar.xml · nonDerivative · entry 1 KANEKO YASUNORI · CIK 0001277503 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,133 F1 · shares: Shares purchased in a private transaction from Dr. William Grossman, Arcus's Chief Medical Officer. F2 · balance_after: Thirty-five thousand (35,000) shares previously held directly by the reporting person were transferred to reporting person's trust. F3 · balance_after: The reporting person's direct ownership includes three thousand (3,000) shares that are Restricted Stock Units that will not vest until June 3, 2021. Read SEC document |
| June 05, 2020 Filed Jun 8, 2020 20:31 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | Exercise / conversionStock Option (Rights to Buy) · Derivative | 35,000 | $0.00 Strike: $7.99 | $0.00 |
DisclosureSEC source: 0001209191-20-034985 · doc4.xml · derivative · entry 7 KANEKO YASUNORI · CIK 0001277503 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 35,000 shares Expires 2029-06-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 05, 2020 Filed Jun 8, 2020 20:31 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | Exercise / conversionCommon Stock | 35,000 | $7.99 | $279,650.00 |
DisclosureSEC source: 0001209191-20-034985 · doc4.xml · nonDerivative · entry 2 KANEKO YASUNORI · CIK 0001277503 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · shares: Represents the exercise of options to purchase common stock by the reporting person. No shares were sold by the reporting person, and the shares received upon the exercise of such options are subject to a lock-up agreement with the underwriters for the Company's recent public offering. Read SEC document |
| June 04, 2020 Filed Jun 8, 2020 20:31 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | GrantStock Option (Right to Buy) · Derivative | 14,000 | $0.00 Strike: $30.05 | $0.00 |
DisclosureSEC source: 0001209191-20-034985 · doc4.xml · derivative · entry 6 KANEKO YASUNORI · CIK 0001277503 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,000 Underlying: Common Stock · 14,000 shares Expires 2030-06-03 F3 · derivative.exercise_date: The option will vest in full on the earlier of (i) 12 months following the date of grant or (ii) the date of the next annual stockholder meeting following the grant. The option becomes fully vested and exercisable in the event the Company is subject to a change in control. Read SEC document |
| June 04, 2020 Filed Jun 8, 2020 20:31 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | GrantCommon Stock | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-034985 · doc4.xml · nonDerivative · entry 1 KANEKO YASUNORI · CIK 0001277503 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 F1 · shares: Represents the grant of restricted stock units that vest 100% on the earlier of June 4, 2021 or the next annual meeting of the stockholders of the issuer. The RSUs will become fully vested in the event the Company is subject to a change in control Read SEC document |
| June 06, 2019 Filed Jun 10, 2019 19:14 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | GrantStock Option (Right to buy) · Derivative | 35,000 | $0.00 Strike: $7.99 | $0.00 |
DisclosureSEC source: 0001209191-19-035752 · doc4.xml · derivative · entry 1 KANEKO YASUNORI · CIK 0001277503 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2029-06-05 F1 · derivative.exercise_date: The option will vest in full on the earlier of (i) 12 months following the date of grant or (ii) the date of the next annual stockholder meeting following the grant. The option becomes fully vested and exercisable in the event the Company is subject to a change in control. Read SEC document |
| October 19, 2018 Filed Oct 19, 2018 20:48 UTC | SI-BONE, Inc. SIBN · Entity 2501 | ConversionSeries 7 Preferred Stock · Derivative | 398,676 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-055698 · doc4.xml · derivative · entry 12 Skyline Venture Partners V LP · CIK 0001419187 · 10% owner Skyline Venture Management V, LLC · CIK 0001434887 · 10% owner Freund John Gordon · CIK 0001296771 · Director · 10% owner KANEKO YASUNORI · CIK 0001277503 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Skyline Venture Partners V, L.P. Disclosed balance after: 0 Underlying: Common Stock · 398,676 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Issuer's Series 4 Preferred Stock, Series 5 Preferred Stock and Series 7 Preferred Stock automatically converted into an equal number of shares of Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date. F1 · price: The Issuer's Series 4 Preferred Stock, Series 5 Preferred Stock and Series 7 Preferred Stock automatically converted into an equal number of shares of Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date. F1 · derivative.exercise_date: The Issuer's Series 4 Preferred Stock, Series 5 Preferred Stock and Series 7 Preferred Stock automatically converted into an equal number of shares of Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date. F1 · derivative.expiration_date: The Issuer's Series 4 Preferred Stock, Series 5 Preferred Stock and Series 7 Preferred Stock automatically converted into an equal number of shares of Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date. F2 · ownership.nature: Shares held by Skyline Venture Partners V, L.P. ("SVP V"). Skyline Venture Management V, LLC ("LLC") is the general partner of SVP V and as such may be deemed to have voting and investment power with respect to the securities of SVP V. John G. Freund, a member of the Issuer's board of directors, together with Yasunori Kaneko, are the managing directors of LLC and each may be deemed to have voting and investment power with respect to the securities held by SVP V. Dr. Freund and Mr. Kaneko disclaim beneficial ownership of such securities, except to the extent of their pecuniary interest therein. Read SEC document |
| October 19, 2018 Filed Oct 19, 2018 20:48 UTC | SI-BONE, Inc. SIBN · Entity 2501 | ConversionSeries 6 Preferred Stock · Derivative | 652,347 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-055698 · doc4.xml · derivative · entry 11 Skyline Venture Partners V LP · CIK 0001419187 · 10% owner Skyline Venture Management V, LLC · CIK 0001434887 · 10% owner Freund John Gordon · CIK 0001296771 · Director · 10% owner KANEKO YASUNORI · CIK 0001277503 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Skyline Venture Partners V, L.P. Disclosed balance after: 0 Underlying: Common Stock · 690,689 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: The Issuer's Series 6 Preferred Stock automatically converted into approximately 1.05878 shares of Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date. F3 · price: The Issuer's Series 6 Preferred Stock automatically converted into approximately 1.05878 shares of Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date. F3 · derivative.exercise_date: The Issuer's Series 6 Preferred Stock automatically converted into approximately 1.05878 shares of Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date. F3 · derivative.expiration_date: The Issuer's Series 6 Preferred Stock automatically converted into approximately 1.05878 shares of Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date. F2 · ownership.nature: Shares held by Skyline Venture Partners V, L.P. ("SVP V"). Skyline Venture Management V, LLC ("LLC") is the general partner of SVP V and as such may be deemed to have voting and investment power with respect to the securities of SVP V. John G. Freund, a member of the Issuer's board of directors, together with Yasunori Kaneko, are the managing directors of LLC and each may be deemed to have voting and investment power with respect to the securities held by SVP V. Dr. Freund and Mr. Kaneko disclaim beneficial ownership of such securities, except to the extent of their pecuniary interest therein. Read SEC document |
| October 19, 2018 Filed Oct 19, 2018 20:48 UTC | SI-BONE, Inc. SIBN · Entity 2501 | ConversionSeries 5 Preferred Stock · Derivative | 792,195 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-055698 · doc4.xml · derivative · entry 10 Skyline Venture Partners V LP · CIK 0001419187 · 10% owner Skyline Venture Management V, LLC · CIK 0001434887 · 10% owner Freund John Gordon · CIK 0001296771 · Director · 10% owner KANEKO YASUNORI · CIK 0001277503 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Skyline Venture Partners V, L.P. Disclosed balance after: 0 Underlying: Common Stock · 792,195 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Issuer's Series 4 Preferred Stock, Series 5 Preferred Stock and Series 7 Preferred Stock automatically converted into an equal number of shares of Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date. F1 · price: The Issuer's Series 4 Preferred Stock, Series 5 Preferred Stock and Series 7 Preferred Stock automatically converted into an equal number of shares of Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date. F1 · derivative.exercise_date: The Issuer's Series 4 Preferred Stock, Series 5 Preferred Stock and Series 7 Preferred Stock automatically converted into an equal number of shares of Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date. F1 · derivative.expiration_date: The Issuer's Series 4 Preferred Stock, Series 5 Preferred Stock and Series 7 Preferred Stock automatically converted into an equal number of shares of Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date. F2 · ownership.nature: Shares held by Skyline Venture Partners V, L.P. ("SVP V"). Skyline Venture Management V, LLC ("LLC") is the general partner of SVP V and as such may be deemed to have voting and investment power with respect to the securities of SVP V. John G. Freund, a member of the Issuer's board of directors, together with Yasunori Kaneko, are the managing directors of LLC and each may be deemed to have voting and investment power with respect to the securities held by SVP V. Dr. Freund and Mr. Kaneko disclaim beneficial ownership of such securities, except to the extent of their pecuniary interest therein. Read SEC document |
| October 19, 2018 Filed Oct 19, 2018 20:48 UTC | SI-BONE, Inc. SIBN · Entity 2501 | ConversionSeries 4 Preferred Stock · Derivative | 2,213,425 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-055698 · doc4.xml · derivative · entry 9 Skyline Venture Partners V LP · CIK 0001419187 · 10% owner Skyline Venture Management V, LLC · CIK 0001434887 · 10% owner Freund John Gordon · CIK 0001296771 · Director · 10% owner KANEKO YASUNORI · CIK 0001277503 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Skyline Venture Partners V, L.P. Disclosed balance after: 0 Underlying: Common Stock · 2,213,425 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Issuer's Series 4 Preferred Stock, Series 5 Preferred Stock and Series 7 Preferred Stock automatically converted into an equal number of shares of Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date. F1 · price: The Issuer's Series 4 Preferred Stock, Series 5 Preferred Stock and Series 7 Preferred Stock automatically converted into an equal number of shares of Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date. F1 · derivative.exercise_date: The Issuer's Series 4 Preferred Stock, Series 5 Preferred Stock and Series 7 Preferred Stock automatically converted into an equal number of shares of Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date. F1 · derivative.expiration_date: The Issuer's Series 4 Preferred Stock, Series 5 Preferred Stock and Series 7 Preferred Stock automatically converted into an equal number of shares of Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date. F2 · ownership.nature: Shares held by Skyline Venture Partners V, L.P. ("SVP V"). Skyline Venture Management V, LLC ("LLC") is the general partner of SVP V and as such may be deemed to have voting and investment power with respect to the securities of SVP V. John G. Freund, a member of the Issuer's board of directors, together with Yasunori Kaneko, are the managing directors of LLC and each may be deemed to have voting and investment power with respect to the securities held by SVP V. Dr. Freund and Mr. Kaneko disclaim beneficial ownership of such securities, except to the extent of their pecuniary interest therein. Read SEC document |
| October 19, 2018 Filed Oct 19, 2018 20:48 UTC | SI-BONE, Inc. SIBN · Entity 2501 | SaleSeries 5 Preferred Stock · Derivative | 23,904 | $14.00 | $334,656.00 |
DisclosureSEC source: 0001209191-18-055698 · doc4.xml · derivative · entry 8 Skyline Venture Partners V LP · CIK 0001419187 · 10% owner Skyline Venture Management V, LLC · CIK 0001434887 · 10% owner Freund John Gordon · CIK 0001296771 · Director · 10% owner KANEKO YASUNORI · CIK 0001277503 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Skyline Venture Partners V, L.P. Disclosed balance after: 792,195 Underlying: Common Stock · 23,904 shares Expires not disclosed F1 · derivative.exercise_price: The Issuer's Series 4 Preferred Stock, Series 5 Preferred Stock and Series 7 Preferred Stock automatically converted into an equal number of shares of Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date. F5 · kind: Immediately prior to the closing of the Issuer's initial public offering, SVP V exercised a warrant to purchase 39,421 shares of Series 5 Preferred Stock at an exercise price of $9.10 per share. The exercise price was paid on a net exercise cashless basis calculated using the Issuer's initial public offering price of $15.00, resulting in the Issuer withholding 23,904 of the warrant shares to pay the exercise price and issuing SVP V the remaining 15,517 shares. F1 · derivative.exercise_date: The Issuer's Series 4 Preferred Stock, Series 5 Preferred Stock and Series 7 Preferred Stock automatically converted into an equal number of shares of Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date. F1 · derivative.expiration_date: The Issuer's Series 4 Preferred Stock, Series 5 Preferred Stock and Series 7 Preferred Stock automatically converted into an equal number of shares of Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date. F2 · ownership.nature: Shares held by Skyline Venture Partners V, L.P. ("SVP V"). Skyline Venture Management V, LLC ("LLC") is the general partner of SVP V and as such may be deemed to have voting and investment power with respect to the securities of SVP V. John G. Freund, a member of the Issuer's board of directors, together with Yasunori Kaneko, are the managing directors of LLC and each may be deemed to have voting and investment power with respect to the securities held by SVP V. Dr. Freund and Mr. Kaneko disclaim beneficial ownership of such securities, except to the extent of their pecuniary interest therein. Read SEC document |
| October 19, 2018 Filed Oct 19, 2018 20:48 UTC | SI-BONE, Inc. SIBN · Entity 2501 | OtherSeries 5 Preferred Stock · Derivative | 39,421 | $0.00 Strike: $9.10 | $0.00 |
DisclosureSEC source: 0001209191-18-055698 · doc4.xml · derivative · entry 7 Skyline Venture Partners V LP · CIK 0001419187 · 10% owner Skyline Venture Management V, LLC · CIK 0001434887 · 10% owner Freund John Gordon · CIK 0001296771 · Director · 10% owner KANEKO YASUNORI · CIK 0001277503 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Skyline Venture Partners V, L.P. Disclosed balance after: 816,099 Underlying: Common Stock · 39,421 shares Expires not disclosed F1 · derivative.exercise_date: The Issuer's Series 4 Preferred Stock, Series 5 Preferred Stock and Series 7 Preferred Stock automatically converted into an equal number of shares of Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date. F1 · derivative.expiration_date: The Issuer's Series 4 Preferred Stock, Series 5 Preferred Stock and Series 7 Preferred Stock automatically converted into an equal number of shares of Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date. F2 · ownership.nature: Shares held by Skyline Venture Partners V, L.P. ("SVP V"). Skyline Venture Management V, LLC ("LLC") is the general partner of SVP V and as such may be deemed to have voting and investment power with respect to the securities of SVP V. John G. Freund, a member of the Issuer's board of directors, together with Yasunori Kaneko, are the managing directors of LLC and each may be deemed to have voting and investment power with respect to the securities held by SVP V. Dr. Freund and Mr. Kaneko disclaim beneficial ownership of such securities, except to the extent of their pecuniary interest therein. Read SEC document |
| October 19, 2018 Filed Oct 19, 2018 20:48 UTC | SI-BONE, Inc. SIBN · Entity 2501 | OtherWarrant (right to buy) · Derivative | 39,421 | $0.00 Strike: $9.10 | $0.00 |
DisclosureSEC source: 0001209191-18-055698 · doc4.xml · derivative · entry 6 Skyline Venture Partners V LP · CIK 0001419187 · 10% owner Skyline Venture Management V, LLC · CIK 0001434887 · 10% owner Freund John Gordon · CIK 0001296771 · Director · 10% owner KANEKO YASUNORI · CIK 0001277503 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Skyline Venture Partners V, L.P. Disclosed balance after: 0 Underlying: Series 5 Preferred Stock · 39,421 shares Expires not disclosed F4 · derivative.exercise_date: Shares subject to the warrant are immediately exercisable. The warrant will expire in connection with the closing of the Issuer's initial public offering. F4 · derivative.expiration_date: Shares subject to the warrant are immediately exercisable. The warrant will expire in connection with the closing of the Issuer's initial public offering. F2 · ownership.nature: Shares held by Skyline Venture Partners V, L.P. ("SVP V"). Skyline Venture Management V, LLC ("LLC") is the general partner of SVP V and as such may be deemed to have voting and investment power with respect to the securities of SVP V. John G. Freund, a member of the Issuer's board of directors, together with Yasunori Kaneko, are the managing directors of LLC and each may be deemed to have voting and investment power with respect to the securities held by SVP V. Dr. Freund and Mr. Kaneko disclaim beneficial ownership of such securities, except to the extent of their pecuniary interest therein. Read SEC document |
| October 19, 2018 Filed Oct 19, 2018 20:48 UTC | SI-BONE, Inc. SIBN · Entity 2501 | PurchaseCommon Stock | 325,000 | $15.00 | $4,875,000.00 |
DisclosureSEC source: 0001209191-18-055698 · doc4.xml · nonDerivative · entry 5 Skyline Venture Partners V LP · CIK 0001419187 · 10% owner Skyline Venture Management V, LLC · CIK 0001434887 · 10% owner Freund John Gordon · CIK 0001296771 · Director · 10% owner KANEKO YASUNORI · CIK 0001277503 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Skyline Venture Partners V, L.P. Disclosed balance after: 4,419,985 F2 · ownership.nature: Shares held by Skyline Venture Partners V, L.P. ("SVP V"). Skyline Venture Management V, LLC ("LLC") is the general partner of SVP V and as such may be deemed to have voting and investment power with respect to the securities of SVP V. John G. Freund, a member of the Issuer's board of directors, together with Yasunori Kaneko, are the managing directors of LLC and each may be deemed to have voting and investment power with respect to the securities held by SVP V. Dr. Freund and Mr. Kaneko disclaim beneficial ownership of such securities, except to the extent of their pecuniary interest therein. Read SEC document |
| October 19, 2018 Filed Oct 19, 2018 20:48 UTC | SI-BONE, Inc. SIBN · Entity 2501 | ConversionCommon Stock | 398,676 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-055698 · doc4.xml · nonDerivative · entry 4 Skyline Venture Partners V LP · CIK 0001419187 · 10% owner Skyline Venture Management V, LLC · CIK 0001434887 · 10% owner Freund John Gordon · CIK 0001296771 · Director · 10% owner KANEKO YASUNORI · CIK 0001277503 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Skyline Venture Partners V, L.P. Disclosed balance after: 4,094,985 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Issuer's Series 4 Preferred Stock, Series 5 Preferred Stock and Series 7 Preferred Stock automatically converted into an equal number of shares of Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date. F2 · ownership.nature: Shares held by Skyline Venture Partners V, L.P. ("SVP V"). Skyline Venture Management V, LLC ("LLC") is the general partner of SVP V and as such may be deemed to have voting and investment power with respect to the securities of SVP V. John G. Freund, a member of the Issuer's board of directors, together with Yasunori Kaneko, are the managing directors of LLC and each may be deemed to have voting and investment power with respect to the securities held by SVP V. Dr. Freund and Mr. Kaneko disclaim beneficial ownership of such securities, except to the extent of their pecuniary interest therein. Read SEC document |
| October 19, 2018 Filed Oct 19, 2018 20:48 UTC | SI-BONE, Inc. SIBN · Entity 2501 | ConversionCommon Stock | 690,689 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-055698 · doc4.xml · nonDerivative · entry 3 Skyline Venture Partners V LP · CIK 0001419187 · 10% owner Skyline Venture Management V, LLC · CIK 0001434887 · 10% owner Freund John Gordon · CIK 0001296771 · Director · 10% owner KANEKO YASUNORI · CIK 0001277503 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Skyline Venture Partners V, L.P. Disclosed balance after: 3,696,309 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: The Issuer's Series 6 Preferred Stock automatically converted into approximately 1.05878 shares of Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date. F2 · ownership.nature: Shares held by Skyline Venture Partners V, L.P. ("SVP V"). Skyline Venture Management V, LLC ("LLC") is the general partner of SVP V and as such may be deemed to have voting and investment power with respect to the securities of SVP V. John G. Freund, a member of the Issuer's board of directors, together with Yasunori Kaneko, are the managing directors of LLC and each may be deemed to have voting and investment power with respect to the securities held by SVP V. Dr. Freund and Mr. Kaneko disclaim beneficial ownership of such securities, except to the extent of their pecuniary interest therein. Read SEC document |
| October 19, 2018 Filed Oct 19, 2018 20:48 UTC | SI-BONE, Inc. SIBN · Entity 2501 | ConversionCommon Stock | 792,195 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-055698 · doc4.xml · nonDerivative · entry 2 Skyline Venture Partners V LP · CIK 0001419187 · 10% owner Skyline Venture Management V, LLC · CIK 0001434887 · 10% owner Freund John Gordon · CIK 0001296771 · Director · 10% owner KANEKO YASUNORI · CIK 0001277503 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Skyline Venture Partners V, L.P. Disclosed balance after: 3,005,620 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Issuer's Series 4 Preferred Stock, Series 5 Preferred Stock and Series 7 Preferred Stock automatically converted into an equal number of shares of Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date. F2 · ownership.nature: Shares held by Skyline Venture Partners V, L.P. ("SVP V"). Skyline Venture Management V, LLC ("LLC") is the general partner of SVP V and as such may be deemed to have voting and investment power with respect to the securities of SVP V. John G. Freund, a member of the Issuer's board of directors, together with Yasunori Kaneko, are the managing directors of LLC and each may be deemed to have voting and investment power with respect to the securities held by SVP V. Dr. Freund and Mr. Kaneko disclaim beneficial ownership of such securities, except to the extent of their pecuniary interest therein. Read SEC document |
| October 19, 2018 Filed Oct 19, 2018 20:48 UTC | SI-BONE, Inc. SIBN · Entity 2501 | ConversionCommon Stock | 2,213,425 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-055698 · doc4.xml · nonDerivative · entry 1 Skyline Venture Partners V LP · CIK 0001419187 · 10% owner Skyline Venture Management V, LLC · CIK 0001434887 · 10% owner Freund John Gordon · CIK 0001296771 · Director · 10% owner KANEKO YASUNORI · CIK 0001277503 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Skyline Venture Partners V, L.P. Disclosed balance after: 2,213,425 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Issuer's Series 4 Preferred Stock, Series 5 Preferred Stock and Series 7 Preferred Stock automatically converted into an equal number of shares of Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date. F2 · ownership.nature: Shares held by Skyline Venture Partners V, L.P. ("SVP V"). Skyline Venture Management V, LLC ("LLC") is the general partner of SVP V and as such may be deemed to have voting and investment power with respect to the securities of SVP V. John G. Freund, a member of the Issuer's board of directors, together with Yasunori Kaneko, are the managing directors of LLC and each may be deemed to have voting and investment power with respect to the securities held by SVP V. Dr. Freund and Mr. Kaneko disclaim beneficial ownership of such securities, except to the extent of their pecuniary interest therein. Read SEC document |
| October 01, 2018 Filed Oct 3, 2018 12:36 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | ConversionSeries E Preferred Stock · Derivative | 18,698,578 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-18-060241 · a4.xml · derivative · entry 6 Skyline Venture Partners V LP · CIK 0001419187 · 10% owner Skyline Venture Management V, LLC · CIK 0001434887 · 10% owner KANEKO YASUNORI · CIK 0001277503 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Skyline Venture Partners V, L.P. Disclosed balance after: 0 Underlying: Common Stock · 514,211 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each share of the issuer's Series E Preferred Stock automatically converted into 0.0275 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F4 · derivative.exercise_date: Each share of the issuer's Series E Preferred Stock automatically converted into 0.0275 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F4 · derivative.expiration_date: Each share of the issuer's Series E Preferred Stock automatically converted into 0.0275 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F2 · ownership.nature: These securities are held of record by Skyline Venture Partners V, L.P. ("Skyline L.P."). Skyline Venture Management V, LLC ("Skyline Management") is the general partner of Skyline L.P. John G. Freund and Yasunori Kaneko, are the managing directors of Skyline Management, and each may be deemed to share voting and investment power over the securities held by Skyline L.P. and disclaims beneficial ownership over such securities except to the extent of their pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. Mr. Freund is a director of the Issuer and, accordingly, files separate Section 16 reports. Read SEC document |
| October 01, 2018 Filed Oct 3, 2018 12:36 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | ConversionSeries D Preferred Stock · Derivative | 12,846,023 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-18-060241 · a4.xml · derivative · entry 5 Skyline Venture Partners V LP · CIK 0001419187 · 10% owner Skyline Venture Management V, LLC · CIK 0001434887 · 10% owner KANEKO YASUNORI · CIK 0001277503 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Skyline Venture Partners V, L.P. Disclosed balance after: 0 Underlying: Common Stock · 520,264 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each share of the issuer's Series D Preferred Stock automatically converted into 0.0405 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F3 · derivative.exercise_date: Each share of the issuer's Series D Preferred Stock automatically converted into 0.0405 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F3 · derivative.expiration_date: Each share of the issuer's Series D Preferred Stock automatically converted into 0.0405 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F2 · ownership.nature: These securities are held of record by Skyline Venture Partners V, L.P. ("Skyline L.P."). Skyline Venture Management V, LLC ("Skyline Management") is the general partner of Skyline L.P. John G. Freund and Yasunori Kaneko, are the managing directors of Skyline Management, and each may be deemed to share voting and investment power over the securities held by Skyline L.P. and disclaims beneficial ownership over such securities except to the extent of their pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. Mr. Freund is a director of the Issuer and, accordingly, files separate Section 16 reports. Read SEC document |
| October 01, 2018 Filed Oct 3, 2018 12:36 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | ConversionSeries C Preferred Stock · Derivative | 25,015,635 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-18-060241 · a4.xml · derivative · entry 4 Skyline Venture Partners V LP · CIK 0001419187 · 10% owner Skyline Venture Management V, LLC · CIK 0001434887 · 10% owner KANEKO YASUNORI · CIK 0001277503 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Skyline Venture Partners V, L.P. Disclosed balance after: 0 Underlying: Common Stock · 925,578 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of the issuer's Series C Preferred Stock automatically converted into 0.0370 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its firm commitment initial public offering (the "IPO") pursuant to a registration statement on Form S-1 (File No. 333-227103) under the Securities Act of 1933, as amended (the "Registration Statement"), and had no expiration date. F1 · derivative.exercise_date: Each share of the issuer's Series C Preferred Stock automatically converted into 0.0370 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its firm commitment initial public offering (the "IPO") pursuant to a registration statement on Form S-1 (File No. 333-227103) under the Securities Act of 1933, as amended (the "Registration Statement"), and had no expiration date. F1 · derivative.expiration_date: Each share of the issuer's Series C Preferred Stock automatically converted into 0.0370 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its firm commitment initial public offering (the "IPO") pursuant to a registration statement on Form S-1 (File No. 333-227103) under the Securities Act of 1933, as amended (the "Registration Statement"), and had no expiration date. F2 · ownership.nature: These securities are held of record by Skyline Venture Partners V, L.P. ("Skyline L.P."). Skyline Venture Management V, LLC ("Skyline Management") is the general partner of Skyline L.P. John G. Freund and Yasunori Kaneko, are the managing directors of Skyline Management, and each may be deemed to share voting and investment power over the securities held by Skyline L.P. and disclaims beneficial ownership over such securities except to the extent of their pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. Mr. Freund is a director of the Issuer and, accordingly, files separate Section 16 reports. Read SEC document |
| October 01, 2018 Filed Oct 3, 2018 12:36 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | ConversionCommon Stock | 514,211 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-18-060241 · a4.xml · nonDerivative · entry 3 Skyline Venture Partners V LP · CIK 0001419187 · 10% owner Skyline Venture Management V, LLC · CIK 0001434887 · 10% owner KANEKO YASUNORI · CIK 0001277503 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Skyline Venture Partners V, L.P. Disclosed balance after: 1,960,053 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · price: Each share of the issuer's Series E Preferred Stock automatically converted into 0.0275 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F2 · ownership.nature: These securities are held of record by Skyline Venture Partners V, L.P. ("Skyline L.P."). Skyline Venture Management V, LLC ("Skyline Management") is the general partner of Skyline L.P. John G. Freund and Yasunori Kaneko, are the managing directors of Skyline Management, and each may be deemed to share voting and investment power over the securities held by Skyline L.P. and disclaims beneficial ownership over such securities except to the extent of their pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. Mr. Freund is a director of the Issuer and, accordingly, files separate Section 16 reports. Read SEC document |
| October 01, 2018 Filed Oct 3, 2018 12:36 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | ConversionCommon Stock | 520,264 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-18-060241 · a4.xml · nonDerivative · entry 2 Skyline Venture Partners V LP · CIK 0001419187 · 10% owner Skyline Venture Management V, LLC · CIK 0001434887 · 10% owner KANEKO YASUNORI · CIK 0001277503 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Skyline Venture Partners V, L.P. Disclosed balance after: 1,445,842 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Each share of the issuer's Series D Preferred Stock automatically converted into 0.0405 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F2 · ownership.nature: These securities are held of record by Skyline Venture Partners V, L.P. ("Skyline L.P."). Skyline Venture Management V, LLC ("Skyline Management") is the general partner of Skyline L.P. John G. Freund and Yasunori Kaneko, are the managing directors of Skyline Management, and each may be deemed to share voting and investment power over the securities held by Skyline L.P. and disclaims beneficial ownership over such securities except to the extent of their pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. Mr. Freund is a director of the Issuer and, accordingly, files separate Section 16 reports. Read SEC document |
| October 01, 2018 Filed Oct 3, 2018 12:36 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | ConversionCommon Stock | 925,578 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-18-060241 · a4.xml · nonDerivative · entry 1 Skyline Venture Partners V LP · CIK 0001419187 · 10% owner Skyline Venture Management V, LLC · CIK 0001434887 · 10% owner KANEKO YASUNORI · CIK 0001277503 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Skyline Venture Partners V, L.P. Disclosed balance after: 925,578 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of the issuer's Series C Preferred Stock automatically converted into 0.0370 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its firm commitment initial public offering (the "IPO") pursuant to a registration statement on Form S-1 (File No. 333-227103) under the Securities Act of 1933, as amended (the "Registration Statement"), and had no expiration date. F2 · ownership.nature: These securities are held of record by Skyline Venture Partners V, L.P. ("Skyline L.P."). Skyline Venture Management V, LLC ("Skyline Management") is the general partner of Skyline L.P. John G. Freund and Yasunori Kaneko, are the managing directors of Skyline Management, and each may be deemed to share voting and investment power over the securities held by Skyline L.P. and disclaims beneficial ownership over such securities except to the extent of their pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. Mr. Freund is a director of the Issuer and, accordingly, files separate Section 16 reports. Read SEC document |
| March 19, 2018 Filed Mar 19, 2018 21:26 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | ConversionSeries C Convertible Preferred Stock · Derivative | 2,565 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-007986 · doc4.xml · derivative · entry 7 KANEKO YASUNORI · CIK 0001277503 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 0 Underlying: Common Stock · 2,565 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The reported security converted into the Issuer's Common Stock on a 1-for-1 basis automatically immediately prior to the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date.Q F2 · price: The reported security converted into the Issuer's Common Stock on a 1-for-1 basis automatically immediately prior to the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date.Q F2 · derivative.exercise_date: The reported security converted into the Issuer's Common Stock on a 1-for-1 basis automatically immediately prior to the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date.Q F2 · derivative.expiration_date: The reported security converted into the Issuer's Common Stock on a 1-for-1 basis automatically immediately prior to the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date.Q Read SEC document |
| March 19, 2018 Filed Mar 19, 2018 21:26 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | ConversionSeries B Convertible Preferred Stock · Derivative | 31,253 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-007986 · doc4.xml · derivative · entry 6 KANEKO YASUNORI · CIK 0001277503 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 0 Underlying: Common Stock · 31,253 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The reported security converted into the Issuer's Common Stock on a 1-for-1 basis automatically immediately prior to the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date.Q F2 · price: The reported security converted into the Issuer's Common Stock on a 1-for-1 basis automatically immediately prior to the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date.Q F2 · derivative.exercise_date: The reported security converted into the Issuer's Common Stock on a 1-for-1 basis automatically immediately prior to the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date.Q F2 · derivative.expiration_date: The reported security converted into the Issuer's Common Stock on a 1-for-1 basis automatically immediately prior to the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date.Q Read SEC document |
| March 19, 2018 Filed Mar 19, 2018 21:26 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | ConversionSeries B Convertible Preferred Stock · Derivative | 252,524 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-007986 · doc4.xml · derivative · entry 5 KANEKO YASUNORI · CIK 0001277503 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Kaneko Investments, LLC Disclosed balance after: 0 Underlying: Common Stock · 252,524 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The reported security converted into the Issuer's Common Stock on a 1-for-1 basis automatically immediately prior to the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date.Q F2 · price: The reported security converted into the Issuer's Common Stock on a 1-for-1 basis automatically immediately prior to the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date.Q F2 · derivative.exercise_date: The reported security converted into the Issuer's Common Stock on a 1-for-1 basis automatically immediately prior to the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date.Q F2 · derivative.expiration_date: The reported security converted into the Issuer's Common Stock on a 1-for-1 basis automatically immediately prior to the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date.Q Read SEC document |
| March 19, 2018 Filed Mar 19, 2018 21:26 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | ConversionSeries A Convertible Preferred Stock · Derivative | 505,050 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-007986 · doc4.xml · derivative · entry 4 KANEKO YASUNORI · CIK 0001277503 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Kaneko Capital, LLC Disclosed balance after: 0 Underlying: Common Stock · 505,050 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The reported security converted into the Issuer's Common Stock on a 1-for-1 basis automatically immediately prior to the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date.Q F2 · price: The reported security converted into the Issuer's Common Stock on a 1-for-1 basis automatically immediately prior to the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date.Q F2 · derivative.exercise_date: The reported security converted into the Issuer's Common Stock on a 1-for-1 basis automatically immediately prior to the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date.Q F2 · derivative.expiration_date: The reported security converted into the Issuer's Common Stock on a 1-for-1 basis automatically immediately prior to the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date.Q Read SEC document |
| March 19, 2018 Filed Mar 19, 2018 21:26 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | ConversionCommon Stock | 33,818 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-007986 · doc4.xml · nonDerivative · entry 3 KANEKO YASUNORI · CIK 0001277503 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 96,948 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The total represents shares received upon conversion of shares of Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock. F2 · price: The reported security converted into the Issuer's Common Stock on a 1-for-1 basis automatically immediately prior to the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date.Q Read SEC document |
| March 19, 2018 Filed Mar 19, 2018 21:26 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | ConversionCommon Stock | 252,524 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-007986 · doc4.xml · nonDerivative · entry 2 KANEKO YASUNORI · CIK 0001277503 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Kaneko Investments, LLC Disclosed balance after: 252,524 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The total represents shares received upon conversion of shares of Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock. F2 · price: The reported security converted into the Issuer's Common Stock on a 1-for-1 basis automatically immediately prior to the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date.Q Read SEC document |
| March 19, 2018 Filed Mar 19, 2018 21:26 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | ConversionCommon Stock | 505,050 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-007986 · doc4.xml · nonDerivative · entry 1 KANEKO YASUNORI · CIK 0001277503 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Kaneko Capital, LLC Disclosed balance after: 505,050 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The total represents shares received upon conversion of shares of Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock. F2 · price: The reported security converted into the Issuer's Common Stock on a 1-for-1 basis automatically immediately prior to the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date.Q Read SEC document |
| December 05, 2017 Filed Dec 8, 2017 00:05 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | OtherCommon Stock | 270 | $0.00 | $0.00 |
DisclosureSEC source: 0001192482-17-000304 · edgar.xml · nonDerivative · entry 2 KANEKO YASUNORI · CIK 0001277503 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By the Kaneko Family Trust Disclosed balance after: 270 F3 · kind: Represents a pro rata in-kind distribution of the shares by Skyline Venture Partners V, L.P. without consideration to the reporting person. Read SEC document |
| December 05, 2017 Filed Dec 8, 2017 00:05 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | OtherCommon Stock | 800,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001192482-17-000304 · edgar.xml · nonDerivative · entry 1 KANEKO YASUNORI · CIK 0001277503 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Skyline Venture Partners V, L.P. Disclosed balance after: 2,149,916 F1 · kind: Represents a pro rata in-kind distribution of the shares by Skyline Venture Partners V, L.P. without consideration to its limited and general partners. F2 · ownership.nature: The shares are held by Skyline Venture Partners V, L.P. The general partner of Skyline Venture Partners V, L.P. is Skyline Venture Management V, LLC. John G. Freund and Yasunori Kaneko are managers of Skyline Venture Management V, LLC. These individuals share voting and investment power over the shares held by Skyline Venture Management, LLC. Dr. Kaneko disclaims beneficial ownership of all the shares held by Skyline Venture Partners V, L.P. except to the extent of his proportionate pecuniary interest therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.